Evidence map›Paper›PMID 33682329›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2021

Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy.

Xiangsheng Liu, Jinhong Jiang, Chong Hyun Chang, Yu-Pei Liao, Jared J Lodico, Ivanna Tang, Emily Zheng, Waveley Qiu, Matthew Lin, Xiang Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiangsheng LiuDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Jinhong JiangCalifornia NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Chong Hyun ChangCalifornia NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Yu-Pei LiaoDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Jared J LodicoCalifornia NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
Ivanna TangDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Emily ZhengDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Waveley QiuDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Matthew LinDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Xiang WangDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Ying JiDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Kuo-Ching MeiDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Andre E NelDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.
Huan MengDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0001-8844-3938

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Use of a Nano-Enabled Platform for Pancreatic Cancer ImmunotherapyR01CA247666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, ZINK, JEFFREY I · 2020 to 2024
$2.6M
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas CancerU01CA198846 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, MENG, HUAN · 2015 to 2019
$2.4M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA247666NCI NIH HHS U01 CA198846
6 · The paper itself

Abstract

In this study a mesoporous silica nanoparticle (MSNP) based platform is developed for high-dose loading of a range of activated platinum (Pt) chemo agents that can be attached to the porous interior through the use of electrostatic and coordination chemistry under weak-basic pH conditions. In addition to the design feature for improving drug delivery, the MSNP can also be encapsulated in a coated lipid bilayer (silicasome), to improve the colloidal stability after intravenous (IV) injection. Improved pharmacokinetics and intratumor delivery of encapsulated activated oxaliplatin (1,2-diamminocyclohexane platinum(II) (DACHPt)) over free drug in an orthotopic Kras-derived pancreatic cancer (PDAC) model is demonstrated. Not only does IV injection of the DACHPt silicasome provide more efficacious cytotoxic tumor cell killing, but can also demonstrate that chemotherapy-induced cell death is accompanied by the features of immunogenic cell death (ICD) as well as a dramatic reduction in bone marrow toxicity. The added ICD features are reflected by calreticulin and high-mobility group box 1 expression, along with increased CD8

Indexed as

Antineoplastic AgentsPancreatic NeoplasmsPharmaceutical PreparationsCell Line, TumorHumansImmunotherapyPlatinumAntineoplastic AgentsPharmaceutical PreparationsPlatinumanti-PD-1 antibodyimmunogenic cell death (ICD)pancreatic cancer (PDAC)platinum drugsilicasome nanocarrier

Identifiers

PMID33682329
PMCPMC8035264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.